VCM
KROS icon

Versant Capital Management’s Keros Therapeutics KROS Stock Holding History

Versant Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31
Closed -$342 – 2807
2026
Q1 		$342 Buy
+31
New +$479 ﹤0.01% 2741
2025
Q2 		– Sell
-643
Closed -$6.55K – 2685
2025
Q1 		$6.55K Buy
+643
New +$7.47K ﹤0.01% 1919

Other funds holding KROS

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM

Versant Capital Management's KROS Position: Q2 2026 in Review

Versant Capital Management sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 31 shares — an estimated $342 sold.

Versant Capital Management first reported a position in KROS in Q1 2025 and held it in 2 quarters. The position peaked at $6.55K in Q1 2025. 14 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Versant Capital Management reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Versant Capital Management sold 31 Keros Therapeutics shares in Q2 2026, an estimated $342.
  • Versant Capital Management first reported a position in Keros Therapeutics in Q1 2025 and held it in 2 quarters.
  • Versant Capital Management's Keros Therapeutics position peaked at $6.55K in Q1 2025.
  • 14 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.